Liu Kang, Li Xiao, Wang Jie, Wang Yichun, Dong Huiyu, Li Jie
Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Department of Urology, The Affiliated Cancer Hospital of Jiangsu Province of Nanjing Medical University, Nanjing, China.
Oncotarget. 2017 Mar 21;8(12):19298-19309. doi: 10.18632/oncotarget.15197.
The contribution of genetic variants in RhoA and ROCK1 genes towards prostate cancer risk has not been reported before. We genotyped six potentially functional genetic variants in a case-control study of 1699 subjects. Overall, we found rs2410 mutant allele and rs2269736 wild allele were risk factors for prostate cancer. Individuals carrying more than two risk alleles were exposed to hazard of prostate cancer. In addition, we demonstrated that the risk of biochemical recurrence might be linked with clinico-pathological characteristics and also genetic factors. Unfortunately, no associations were observed between all polymorphisms and clinico-pathological characteristics. Moreover, no genotype was found as significant independent prognostic predictor for biochemical recurrence survival in Multivariate Cox regression analysis after Bonferroni correction. Our study is the first to clarify the relations of genetic variants of RhoA and ROCK1 genes with development, progression and prognosis of prostate cancer. These variants may be promising novel biomarkers to facilitate clinical treatment decision-making.
RhoA和ROCK1基因中的遗传变异对前列腺癌风险的贡献此前尚未见报道。我们在一项针对1699名受试者的病例对照研究中对六个潜在的功能性遗传变异进行了基因分型。总体而言，我们发现rs2410突变等位基因和rs2269736野生等位基因是前列腺癌的危险因素。携带两个以上风险等位基因的个体面临前列腺癌风险。此外，我们证明生化复发风险可能与临床病理特征以及遗传因素有关。遗憾的是，未观察到所有多态性与临床病理特征之间存在关联。此外，在Bonferroni校正后的多变量Cox回归分析中，未发现任何基因型是生化复发生存的显著独立预后预测指标。我们的研究首次阐明了RhoA和ROCK1基因的遗传变异与前列腺癌发生、发展及预后的关系。这些变异可能是有助于临床治疗决策的有前景的新型生物标志物。
